This includes BCR-ABL in chronic myelogenous leukemia (CML), ALK and ROS1 kinase fusions in non-small cell lung cancer, as well as TRK fusions in solid cancers [4–7]. This evidence concerns the gene ROS1 and chronic myelogenous leukemia, BCR-ABL1 positive.